Clinical trial
An Open Label, Single Dose, Dose Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Semaglutide Extended-release Injectable Suspension in Normal Healthy, Adult, Human Study Participants Under Fasting Condition
NCT06422624 is registered in ClinicalTrials.gov with Bostal Drug Delivery Co., Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open Label, Single Dose, Dose Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Semaglutide Extended-release Injectable Suspension in Normal Healthy, Adult, Human Study Participants Under Fasting Condition
- Lead sponsor
- Bostal Drug Delivery Co., Ltd
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- August 31, 2024
- Completion date
- November 30, 2024
- Enrollment
- 14 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.